<DOC>
	<DOCNO>NCT00472329</DOCNO>
	<brief_summary>Major Objectives A . To determine whether stable allogeneic hematopoietic engraftment safely establish patient reject ( &lt; 5 % T Cell Chimerism ) previous allogeneic hematopoietic stem cell graft use allogeneic SCT HLA-Identical non-identical family donor unrelated donor , fludarabine ( 150mg/m2 ) TBI ( 400cGy ) , post-transplantation immunosuppression utilize tacrolimus MMF . B . To evaluate incidence transplant relate mortality . Minor Objectives A . To evaluate incidence acute chronic GVHD second allogeneic HCT utilize Tac/MMF peripheral blood stem cell match mis-matched allogeneic donor . B . To evaluate disease response survival second allogeneic SCT . C. To evaluate need DLI second transplant either disease control persistent mixed chimerism .</brief_summary>
	<brief_title>Fludarabine 400 CGY Total Body Irradiation Recipients HLA-Matched Mis-Matched Family Unrelated Donor Hematopoietic Stem Cell Transplants Who Have Rejected Their First Allogeneic Stem Cell Transplant</brief_title>
	<detailed_description>This protocol evaluate use Fludarabine ( 150mg/m2 ) TBI ( 400cGy ) pre-transplant condition second allogeneic stem cell transplant initial graft rejection . Preliminary data suggest combination Flu/TBI propose dos safer effective prior second transplantation regimen publish date . As perform non-myeloablative transplantation expect issue arise frequently . The preliminary data available indicate propose regimen safest effective instill donor hematopoiesis initial graft reject . We also wish evaluate safety effectiveness Tacrolimus MMF GVHD prophylaxis patient receive second transplant . Tac/MMF current GVHD prophylaxis regimen . It proven well tolerate provide good protection GVHD , even heavily pretreated patient . We propose use standard first transplant GVHD prophylaxis prevent GVHD second transplantation . DLI may give presence disease progression mixed chimerism clinically indicate .</detailed_description>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<criteria>Any patient reject previous allogeneic transplant ( relate unrelated ) rejection base chimerism data peripheral blood specimen show loss donor T Cells . 1 . Available HLAidentical , oneantigen mismatch sibling donor , phenotypically HLAmatched family member , phenotypically match unrelated donor , 9/10 match unrelated donor negative crossmatch . 2 . Age â‰¤ 75 year . 3 . Patients fail engraft sign early relapse autologous transplant may consider protocol salvage treatment present RMBMTP Clinical Care meet majority group agree reasonable treatment option . 1 . Patients whose low donor chimerism felt due rapidly progressive hematological malignancy , unless treat minimal disease state additional treatment . 2 . Patients active uncontrolled CNS involvement malignancy . 3 . Fertile men woman unwilling use contraceptive technique 12 month follow treatment . 4 . Females pregnant . 5 . Patients HIV positive 6 . Organ dysfunction felt due conditioning first transplant include follow : Left ventricle ejection fraction &lt; 35 % . DLCO &lt; 35 % predict , receive continuous supplementary oxygen . Karnofsky score &lt; 50 patient &lt; 60 year , &lt; 70 patient age 60 69 year ( see appendix B ) . Creatinine clearance &lt; 40 ml/min . Patients endorgan toxicity may present RMBMTP Patient Care Conference . If majority opinion treatment safe option patient reject first transplant , allow undergo treatment , informed consent sign . Patients positive PRA antidonor T B cell ( + ) consider treatment protocol option available . They eligible another research study . The transplantation group must majority opinion best available option patient question . In patient either condition , acceptable stem cell source peripheral blood .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>74 Years</maximum_age>
	<verification_date>June 2014</verification_date>
</DOC>